Novavax (NVAX) downgraded to Underperform by BofA due to uncertain growth outlook despite cost-cutting measures. Read more ...

As previously reported, BofA downgraded Novavax (NVAX) to Underperform from Neutral with a price target of $7, down from $9, citing the recent ...

Novavax, Inc. (NASDAQ:NVAX) is a biotechnology company focused on recombinant protein-based vaccines using nanoparticle and ...

D.C. drugmaker Vanda Pharmaceuticals just landed a significant victory, setting the stage for a potential treatment to ...

The move would add another barrier for parents who want to vaccinate healthy children ahead of the respiratory virus season.

“We’ve stepped back into the world that we lived in before the [CDC’s vaccine advisory committee] was created,” said Dr.

Drastic changes are brewing at the FDA, as newly appointed Commissioner Dr. Marty Makary indicates a shift toward stricter scientific accountability in vaccine approvals. In a notable departure from ...

The U.S. Food and Drug Administration may not renew its authorization for Pfizer's COVID-19 vaccine approved for children ...

Earlier this summer the FDA asked Moderna for more efficacy data on its flu vaccine before it could review an mRNA-based combination shot that targets both influenza and COVID-19. Now, the entire ...

Novavax had applied for a license for its shot to prevent COVID-19 for anyone over 12 years old, effectively converting it to a traditional approval from the emergency use authorizations the FDA ...

Novavax’s vaccine is the only protein-based coronavirus vaccine available in the U.S. Moderna’s vaccine is an updated, lower-dose version of its existing mRNA-based vaccine.

WASHINGTON (AP) — The government’s top vaccine official working under Health Secretary Robert F. Kennedy Jr. recently restricted the approval of two COVID-19 vaccines, disregarding ...